

Estrogen Stimulates Gene Expression and Protein Production in Human Osteoblastic Cells*

Endocrinology

140, 4367-4370

DOI: [10.1210/endo.140.9.7131](https://doi.org/10.1210/endo.140.9.7131)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Molecular and cellular mechanisms of estrogen action on the skeleton. , 1999, 75, 123-132.		61
2	Bone Anabolic Effects of PTH(1-34) and Salmon Calcitonin in Ovariectomy- and Ovariectomy-Steroid-Induced Osteopenic Rats: A Histomorphometric and Biomechanical Study. The Japanese Journal of Pharmacology, 2000, 82, 240-246.	1.2	8
3	Breakthrough in bone: the molecular mechanism of osteoclast/osteoblast coupling revealed. Current Opinion in Orthopaedics, 2000, 11, 329-335.	0.3	15
4	Studies of human osteoblasts in vitro: Estrogen actions and interactions with other hormones at different stages of differentiation. Drug Development Research, 2000, 49, 174-186.	1.4	11
5	New approaches to the treatment of osteoporosis. Current Opinion in Chemical Biology, 2000, 4, 383-393.	2.8	32
6	Molecular control of bone remodeling and osteoporosis. Experimental Gerontology, 2000, 35, 947-956.	1.2	82
7	The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption. Journal of Bone and Mineral Research, 2000, 15, 2-12.	3.1	1,031
8	Bone Resorption by Osteoclasts. Science, 2000, 289, 1504-1508.	6.0	3,355
9	Osteoprotegerin and its Ligand: A New Paradigm for Regulation of Osteoclastogenesis and Bone Resorption. Osteoporosis International, 2000, 11, 905-913.	1.3	255
10	Hormonal regulation of physiological cell turnover and apoptosis. Cell and Tissue Research, 2000, 301, 101-124.	1.5	58
11	Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis*. Endocrine Reviews, 2000, 21, 115-137.	8.9	1,707
12	The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy. Nephrology Dialysis Transplantation, 2000, 15, 945-950.	0.4	25
13	Links Among Growth Factors, Hormones, and Nuclear Factors With Essential Roles in Bone Formation. Critical Reviews in Oral Biology and Medicine, 2000, 11, 409-422.	4.4	68
14	The Role of Receptor Activator of Nuclear Factor- κ B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2355-2363.	1.8	150
15	The parathyroid hormone, its fragments and analogues - potent bone-builders for treating osteoporosis. Expert Opinion on Investigational Drugs, 2000, 9, 1293-1315.	1.9	20
16	Age-Related Decline in Osteoprotegerin Expression by Human Bone Marrow Cells Cultured in Three-Dimensional Collagen Sponges. Biochemical and Biophysical Research Communications, 2000, 268, 669-672.	1.0	80
17	Correlation of estradiol, parathyroid hormone, interleukin-6, and soluble interleukin-6 receptor during the normal menstrual cycle. Bone, 2000, 26, 79-85.	1.4	38
18	Estrogen receptor transcription and transactivation Basic aspects of estrogen action. Breast Cancer Research, 2000, 2, 360-6.	2.2	122

#	ARTICLE	IF	CITATIONS
19	Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. , 2000, 21, 115-137.		798
20	Mechanisms of diethylstilbestrol-induced calcium movement in MG63 human osteosarcoma cells. Toxicology Letters, 2001, 122, 245-253.	0.4	14
21	Regulation of Osteoprotegerin Secretion from Primary Cultures of Human Bone Marrow Stromal Cells. Biochemical and Biophysical Research Communications, 2001, 280, 831-835.	1.0	94
22	Immunological Study on Circulating Murine Osteoprotegerin/Osteoclastogenesis Inhibitory Factor (OPG/OCIF): Possible Role of OPG/OCIF in the Prevention of Osteoporosis in Pregnancy. Biochemical and Biophysical Research Communications, 2001, 288, 217-224.	1.0	33
23	EFFECT OF OESTRADIOL ON CYTOKINE PRODUCTION IN IMMORTALIZED HUMAN MARROW STROMAL CELL LINES. Cytokine, 2001, 16, 126-130.	1.4	18
24	Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine and Growth Factor Reviews, 2001, 12, 9-18.	3.2	180
25	Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification†††This work originated at the R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey, USA.. Steroids, 2001, 66, 663-671.	0.8	8
26	Sex Steroids and Bone. Physiological Reviews, 2001, 81, 419-447.	13.1	431
27	Mechanisms of Estrogen Action. Physiological Reviews, 2001, 81, 1535-1565.	13.1	1,671
28	Local and Systemic Factors in the Pathogenesis of Osteoporosis. , 2001, , 19-27.		0
29	17- β -Estradiol Affects Brain Protein Synthesis Rate in Ovariectomized Female Rats. Journal of Nutrition, 2001, 131, 123-126.	1.3	12
30	Role of receptor activator of nuclear factor- κ B ligand and osteoprotegerin in bone cell biology. Journal of Molecular Medicine, 2001, 79, 243-253.	1.7	492
31	Osteoprotegerin and Osteoprotegerin-Ligand Balance: a New Paradigm in Bone Metabolism Providing New Therapeutic Targets. Clinical Rheumatology, 2001, 20, 3-9.	1.0	35
32	Alterations in osteoclast morphology following long-term 17beta-estradiol administration in the mouse. BMC Cell Biology, 2001, 2, 3.	3.0	6
33	Receptor activator of nuclear factor- κ B ligand and osteoprotegerin. Cancer, 2001, 92, 460-470.	2.0	166
34	Causes of Age-Related Bone Loss and Bone Fragility: An Alternative View. Journal of Bone and Mineral Research, 2001, 16, 1948-1952.	3.1	63
35	The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women. Journal of Bone and Mineral Research, 2001, 16, 348-360.	3.1	418
36	Expression Profiles of Receptor Activator of Nuclear Factor κ B Ligand, Receptor Activator of Nuclear Factor κ B, and Osteoprotegerin Messenger RNA in Aged and Ovariectomized Rat Bones. Journal of Bone and Mineral Research, 2001, 16, 1416-1425.	3.1	96

#	ARTICLE	IF	CITATIONS
37	Pathogenesis of postmenopausal osteoporosis. , 2001, 2, 5-12.		24
38	Postmenopausal Osteoporosis. , 2001, , 85-101.		6
39	Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis. Molecular Therapy, 2001, 3, 197-205.	3.7	93
40	Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF- κ B Ligand (RANKL)-induced JNK Activation. Journal of Biological Chemistry, 2001, 276, 8836-8840.	1.6	309
41	Osteoprotegerin, a Crucial Regulator of Bone Metabolism, Also Regulates B Cell Development and Function. Journal of Immunology, 2001, 166, 1482-1491.	0.4	174
42	Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. Journal of Endocrinology, 2001, 171, 425-433.	1.2	82
43	Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. European Journal of Endocrinology, 2001, 145, 199-205.	1.9	32
44	Effects of Gonadal Steroid Suppression on Skeletal Sensitivity to Parathyroid Hormone in Men ¹ . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 511-516.	1.8	54
45	Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status ¹ . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3162-3165.	1.8	186
46	17 β -Estradiol Stimulates Expression of Osteoprotegerin by a Mouse Stromal Cell Line, ST-2, via Estrogen Receptor- α *. Endocrinology, 2001, 142, 2205-2212.	1.4	173
47	OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats. Endocrinology, 2001, 142, 4295-4304.	1.4	121
48	Minireview: The OPG/RANKL/RANK System. Endocrinology, 2001, 142, 5050-5055.	1.4	1,199
49	Bone growth stimulators New tools for treating bone loss and mending fractures. Vitamins and Hormones, 2002, 65, 1-80.	0.7	14
50	Role of RANKL and RANK in bone loss and arthritis. Annals of the Rheumatic Diseases, 2002, 61, 32ii-39.	0.5	176
51	Estrogen Inhibition of PTH-Stimulated Osteoclast Formation and Attachment in Vitro: Involvement of Both PKA and PKC. Endocrinology, 2002, 143, 627-635.	1.4	35
52	Circulating Estradiol and Osteoprotegerin as Determinants of Bone Turnover and Bone Density in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4470-4475.	1.8	175
53	Estrogen Receptor-Related Receptor α Impinges on the Estrogen Axis in Bone: Potential Function in Osteoporosis. Endocrinology, 2002, 143, 3658-3670.	1.4	56
54	Double Mutations in Klotho and Osteoprotegerin Gene Loci Rescued Osteopetrotic Phenotype. Endocrinology, 2002, 143, 4711-4717.	1.4	18

#	ARTICLE	IF	CITATIONS
55	Effect of Estrogen versus Testosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1550-1554.	1.8	167
56	Pathophysiology of Osteoporosis. , 2002, , 1275-1289.		6
57	Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. <i>European Journal of Endocrinology</i> , 2002, 147, 269-273.	1.9	67
58	Localization of Osteoprotegerin (OPG) on Bone Surfaces and Cement Lines in Rat Tibia. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 945-953.	1.3	16
59	RANK Ligand and Osteoprotegerin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 549-553.	1.1	356
60	Receptor Activator for Nuclear Factor Kappa B Ligand and Osteoprotegerin: Regulators of Bone Physiology and Immune Responses/Potential Therapeutic Agents and Biochemical Markers. <i>Annals of Clinical Biochemistry</i> , 2002, 39, 551-556.	0.8	38
61	Bone Resorption in Chronic Otitis media: The Role of the Osteoclast. <i>Orl</i> , 2002, 64, 95-107.	0.6	46
62	Tissue culture models for studies of hormone and vitamin action in bone cells. <i>Vitamins and Hormones</i> , 2002, 64, 101-151.	0.7	23
63	Comparison of the effects of 17 β -E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 785-790.	1.8	33
64	Effect of Dietary Protein Quantity and Quality on the Brain Protein Synthesis Rate in Ovariectomized Female Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2002, 50, 1731-1735.	2.4	8
65	Changes in Proinflammatory Cytokine Activity after Menopause. <i>Endocrine Reviews</i> , 2002, 23, 90-119.	8.9	760
66	RANK-LANDRANK: T Cells, Bone Loss, and Mammalian Evolution. <i>Annual Review of Immunology</i> , 2002, 20, 795-823.	9.5	741
67	Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. <i>American Journal of Kidney Diseases</i> , 2002, 39, 525-532.	2.1	158
68	Sex Steroids and the Construction and Conservation of the Adult Skeleton. <i>Endocrine Reviews</i> , 2002, 23, 279-302.	8.9	1,471
69	Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2002, 293, 451-455.	1.0	21
70	Estrogen deficiency results in enhanced expression of Smoothed of the Hedgehog signaling in the thymus and affects thymocyte development. <i>International Immunopharmacology</i> , 2002, 2, 823-833.	1.7	20
71	Research Communication: Dietary Genistein Affects Brain Protein Synthesis Rates in Ovariectomized Female Rats. <i>Journal of Nutrition</i> , 2002, 132, 2055-2058.	1.3	7
72	Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 3121-3135.	6.7	49

#	ARTICLE	IF	CITATIONS
73	Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. <i>Journal of Cellular Biochemistry</i> , 2002, 84, 725-735.	1.2	93
74	Further characterization of human fetal osteoblastic hFOB 1.19 and hFOB/ER α cells: Bone formation in vivo and karyotype analysis using multicolor fluorescent in situ hybridization. <i>Journal of Cellular Biochemistry</i> , 2002, 87, 9-15.	1.2	100
75	Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. <i>Journal of Cellular Biochemistry</i> , 2002, 84, 1-11.	1.2	29
76	Correlates of Osteoprotegerin Levels in Women and Men. <i>Osteoporosis International</i> , 2002, 13, 394-399.	1.3	177
77	Effects of locally-delivered human macrophage products and estrogen on murine inflammatory bone resorption. <i>Journal of Periodontal Research</i> , 2002, 37, 101-109.	1.4	3
78	Down-Regulation of Osteoclast Differentiation by Daidzein via Caspase 3. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 630-638.	3.1	83
79	Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1245-1255.	3.1	170
80	Osteoclastogenesis, Bone Resorption, and Osteoclast-Based Therapeutics. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 599-609.	3.1	151
81	Metabolic Acidosis Stimulates RANKL RNA Expression in Bone Through a Cyclo-oxygenase-Dependent Mechanism. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1317-1325.	3.1	90
82	Estrogen Potentiates the Combined Effects of Transforming Growth Factor- β 2 and Tumor Necrosis Factor- α on Adult Human Osteoblast-like Cell Prostaglandin E2 Biosynthesis. <i>Calcified Tissue International</i> , 2003, 73, 565-574.	1.5	3
83	Osteoprotegerin serum levels in women: Correlation with age, bone mass, bone turnover and fracture status. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 291-297.	1.0	50
84	Role of cytokines in postmenopausal bone loss. <i>Current Osteoporosis Reports</i> , 2003, 1, 53-58.	1.5	36
85	Effects of the Natural and Artificial Menstrual Cycle on the Production of Osteoprotegerin and the Bone Resorptive Cytokines IL-1 β and IL-6. <i>Calcified Tissue International</i> , 2003, 72, 18-23.	1.5	19
86	Gene expression studies of osteoporosis: implications for microarray research. <i>Osteoporosis International</i> , 2003, 14, 451-461.	1.3	13
87	Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. <i>Osteoporosis International</i> , 2003, 14, 750-756.	1.3	60
88	Influence of Cortisol, Gonadal Steroids and an Energy Deficit on Biochemical Indicators of Bone Turnover in Swine. <i>Transboundary and Emerging Diseases</i> , 2003, 50, 79-87.	0.6	7
89	Molecular mechanisms underlying osteoclast formation and activation. <i>Experimental Gerontology</i> , 2003, 38, 605-614.	1.2	119
90	RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. <i>Cancer</i> , 2003, 97, 802-812.	2.0	97

#	ARTICLE	IF	CITATIONS
91	Pathogenesis of osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2003, 32, 15-24.	1.2	88
92	The role of estrogens in men and androgens in women. <i>Endocrinology and Metabolism Clinics of North America</i> , 2003, 32, 195-218.	1.2	38
93	Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. <i>Bone</i> , 2003, , .	1.4	0
94	Delitto Perfetto Targeted Mutagenesis in Yeast with Oligonucleotides. , 2003, , 189-207.		29
95	Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. <i>Bone</i> , 2003, 33, 860-866.	1.4	9
96	Genetic Disorders of the Skeleton: A Developmental Approach. <i>American Journal of Human Genetics</i> , 2003, 73, 447-474.	2.6	158
97	Biology of the TRANCE axis. <i>Cytokine and Growth Factor Reviews</i> , 2003, 14, 251-263.	3.2	177
98	The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. <i>Bone</i> , 2003, 32, 136-141.	1.4	264
99	Serum levels of osteoprotegerin increase with age in a healthy adult population. <i>Bone</i> , 2003, 32, 681-686.	1.4	159
100	Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency-relationship with bone turn-over. <i>Bone</i> , 2003, 33, 638-645.	1.4	23
101	The molecular actions of thyroid hormone in bone. <i>Trends in Endocrinology and Metabolism</i> , 2003, 14, 356-364.	3.1	219
102	Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. <i>Arthritis Research</i> , 2003, 5, R202.	2.0	37
103	Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. <i>Journal of Endocrinology</i> , 2003, 177, 423-433.	1.2	76
104	GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. <i>European Journal of Endocrinology</i> , 2003, 148, 185-191.	1.9	19
105	Effects of Triiodothyronine and Estrogen Administration on Bone Mass, Mineral Content and Bone Strength in Male Rats. <i>Hormone and Metabolic Research</i> , 2003, 35, 527-531.	0.7	6
106	Molecular and Genetic Mechanisms of Osteoporosis: Implication for Treatment. <i>Current Molecular Medicine</i> , 2003, 3, 737-757.	0.6	15
107	Serum Osteoprotegerin as a Determinant of Bone Metabolism in a Longitudinal Study of Human Pregnancy and Lactation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5361-5365.	1.8	74
108	Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4206-4213.	1.8	91

#	ARTICLE	IF	CITATIONS
109	Effects of a Triphasic Combination Oral Contraceptive Containing Norgestimate/Ethinyl Estradiol on Biochemical Markers of Bone Metabolism in Young Women with Osteopenia Secondary to Hypothalamic Amenorrhea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3651-3656.	1.8	40
110	Age-Related Changes in Cortical Bone Content of Insulin-Like Growth Factor Binding Protein (IGFBP)-3, IGFBP-5, Osteoprotegerin, and Calcium in Postmenopausal Osteoporosis: A Cross-Sectional Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1014-1018.	1.8	51
111	Understanding osteoclast formation and function: implications for future therapies for osteoporosis. <i>Current Opinion in Orthopaedics</i> , 2003, 14, 341-350.	0.3	10
113	Osteoporose e erosões osseas focais na artrite reumatóide: da patogênese ao tratamento. <i>Revista Brasileira De Reumatologia</i> , 2004, 44, 347-354.	0.8	4
114	Osteoprotegerin-Receptor Activator of Nuclear Factor- κ B Ligand Ratio: A New Approach to Osteoporosis Treatment?. <i>Southern Medical Journal</i> , 2004, 97, 506-511.	0.3	27
115	Bone Formation. , 2004, , .		10
116	Effects of the Phytoestrogen Genistein on the Circulating Soluble Receptor Activator of Nuclear Factor κ B Ligand-Osteoprotegerin System in Early Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 188-192.	1.8	48
117	Testosterone Increases Osteoprotegerin mRNA Expression in Mouse Osteoblast Cells. <i>Hormone and Metabolic Research</i> , 2004, 36, 674-678.	0.7	64
118	Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 369-379.	1.3	33
119	Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. <i>Endocrine-Related Cancer</i> , 2004, 11, 771-779.	1.6	30
120	The Phytoestrogen Genistein Enhances Osteogenesis and Represses Adipogenic Differentiation of Human Primary Bone Marrow Stromal Cells. <i>Endocrinology</i> , 2004, 145, 848-859.	1.4	168
121	Effect of Adding Dietary Methionine to a Low Soy Protein Diet on the Brain Protein Synthesis Rate in Ovariectomized Female Rats. <i>Nutritional Neuroscience</i> , 2004, 7, 185-190.	1.5	6
122	The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. <i>Clinical Endocrinology</i> , 2004, 61, 244-249.	1.2	31
123	Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. <i>Clinical Endocrinology</i> , 2004, 61, 560-566.	1.2	72
124	Osteoprotegerin and RANKL in the Pathogenesis of Thalassemia-Induced Osteoporosis: New Pieces of the Puzzle. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 722-727.	3.1	98
125	Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. <i>Journal of Bone and Mineral Metabolism</i> , 2004, 22, 132-138.	1.3	83
126	Calcium sensing and cell signaling processes in the local regulation of osteoclastic bone resorption. <i>Biological Reviews</i> , 2004, 79, 79-100.	4.7	44
127	Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. <i>Clinical Endocrinology</i> , 2004, 60, 214-219.	1.2	49

#	ARTICLE	IF	CITATIONS
128	A low dose of daidzein acts as an ER α -selective agonist in trabecular osteoblasts of young female piglets. <i>Journal of Cellular Physiology</i> , 2004, 200, 253-262.	2.0	59
129	Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. <i>Journal of Theoretical Biology</i> , 2004, 229, 293-309.	0.8	352
130	Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification. <i>Endocrine Reviews</i> , 2004, 25, 629-672.	8.9	238
131	Androgens and Bone. <i>Endocrine Reviews</i> , 2004, 25, 389-425.	8.9	611
132	Significance of primary hyperparathyroidism in the management of osteoporosis. <i>Otolaryngologic Clinics of North America</i> , 2004, 37, 751-761.	0.5	11
133	Bone mineral density and serum levels of estradiol and osteoprotegerin in postmenopausal women with viral cirrhosis. <i>Gastroenterology</i> , 2004, 126, 1225-1226.	0.6	7
134	Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 490.	3.8	824
135	Bone health and aging: implications for menopause. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 741-759.	1.2	25
136	The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. <i>Cytokine and Growth Factor Reviews</i> , 2004, 15, 457-475.	3.2	552
137	Bone metabolism in relation to alterations in systemic growth hormone. <i>Growth Hormone and IGF Research</i> , 2004, 14, 404-417.	0.5	46
138	Recovery of pregnancy mediated bone loss during lactation. <i>Bone</i> , 2004, 34, 570-578.	1.4	104
139	Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. <i>Bone</i> , 2004, 35, 334-342.	1.4	68
140	Skeletal changes in osteoprotegerin and receptor activator of nuclear factor- κ B ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. <i>Bone</i> , 2004, 35, 256-265.	1.4	53
141	Nucleosides and nucleotides in the tumor necrosis factor receptor ligand and superfamily with importance for physiological and pathological bone resorption. <i>Critical Reviews in Oral Biology and Medicine</i> , 2004, 15, 64-81.	4.4	117
142	17 β -Estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. <i>Blood</i> , 2004, 104, 1404-1410.	0.6	145
143	Suppressive Effect of Dai-bofu-to on Collagen-Induced Arthritis. <i>Biological and Pharmaceutical Bulletin</i> , 2004, 27, 857-862.	0.6	5
144	New perspectives on parathyroid hormone therapy. <i>Current Opinion in Rheumatology</i> , 2005, 17, 467-474.	2.0	5
145	Clinical Disorders Associated with Alterations in Bone Resorption. , 2005, , 108-127.		2

#	ARTICLE	IF	CITATIONS
146	Isopropanolic Extract of Black Cohosh Stimulates Osteoprotegerin Production by Human Osteoblasts. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 2036-2043.	3.1	32
147	Estrogen and Testosterone Use Different Cellular Pathways to Inhibit Osteoclastogenesis and Bone Resorption. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 2224-2232.	3.1	162
148	The effects of C161â†T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-Î³ gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 1087-1093.	0.7	36
149	Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. <i>Clinical Endocrinology</i> , 2005, 62, 92-98.	1.2	68
150	The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. <i>Clinical Endocrinology</i> , 2005, 62, 349-353.	1.2	36
151	Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. <i>Immunological Reviews</i> , 2005, 208, 30-49.	2.8	284
152	The role of the immune system in the pathophysiology of osteoporosis. <i>Immunological Reviews</i> , 2005, 208, 207-227.	2.8	307
153	Differential subcellular distribution of estrogen receptor isoforms: Localization of ERÎ± in the nucleoli and ERÎ² in the mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2 cell lines. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005, 1745, 382-392.	1.9	64
154	Esteroides sexuales y hueso: Â¿tiene sexo el hueso?. <i>Revista EspaÃ±ola De Enfermedades MetabÃ³licas Â“seas</i> , 2005, 14, 5-14.	0.0	1
155	Bone marrow stromal cells express two distinct splice variants of ER-? that are regulated by estrogen. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 88-97.	1.2	11
156	Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 1244-1253.	1.2	64
157	Genetic Polymorphisms of OPG, RANK, and ESR1 and Bone Mineral Density in Korean Postmenopausal Women. <i>Calcified Tissue International</i> , 2005, 77, 152-159.	1.5	65
158	Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. <i>Osteoporosis International</i> , 2005, 16, 417-423.	1.3	98
159	The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. <i>Osteoporosis International</i> , 2005, 16, 1368-1374.	1.3	83
160	Bone mass and mineral metabolism in HIV+ postmenopausal women. <i>Osteoporosis International</i> , 2005, 16, 1345-1352.	1.3	106
161	The effect of vitamin K2 on bone metabolism in aged female rats. <i>Osteoporosis International</i> , 2005, 16, 1604-1610.	1.3	22
162	Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. <i>Osteoporosis International</i> , 2005, 16, 1487-1494.	1.3	43
163	Roles for NF-Î²B and c-Fos in osteoclasts. <i>Journal of Bone and Mineral Metabolism</i> , 2005, 23, 11-15.	1.3	86

#	ARTICLE	IF	CITATIONS
164	Osteoprotegerin as a potential therapy for osteoporosis. <i>Current Osteoporosis Reports</i> , 2005, 3, 121-125.	1.5	11
165	Differential effects of 17 β -estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 289, E105-E112.	1.8	40
166	Inflammatory Mediators as Potential Therapeutic Targets in the Spine. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 257-266.	3.1	20
167	Endocrine Control of Body Composition in Infancy, Childhood, and Puberty. <i>Endocrine Reviews</i> , 2005, 26, 114-146.	8.9	367
168	A Randomized Placebo-Controlled Trial of Short-Term Graded Transdermal Estradiol in Healthy Gonadotropin-Releasing Hormone Agonist-Suppressed Pre- and Postmenopausal Women: Effects on Serum Markers of Bone Turnover, Insulin-Like Growth Factor-I, and Osteoclastogenic Mediators. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1953-1960.	1.8	10
169	Statins Modulate the Levels of Osteoprotegerin/Receptor Activator of NF κ B Ligand mRNA in Mouse Bone-cell Cultures. <i>Hormone and Metabolic Research</i> , 2005, 37, 589-592.	0.7	62
170	Tumor Necrosis Factor- α Mediates Osteopenia Caused by Depletion of Antioxidants. <i>Endocrinology</i> , 2005, 146, 113-118.	1.4	93
171	Osteoclast: Origin and Differentiation. , 2005, , 1-23.		7
172	Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. <i>International Journal of Molecular Medicine</i> , 2005, 15, 827.	1.8	5
173	Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κ B Ligand: Clinical Utility in Metabolic Bone Disease Assessment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6323-6331.	1.8	204
174	Pathophysiology of Age-Related Bone Loss and Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 1015-1030.	1.2	277
175	Hepatic osteodystrophy: Does the osteoprotegerin/receptor activator of nuclear factor- κ B ligand system play a role?. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 677-682.	1.8	14
176	Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 49-54.	1.5	44
177	Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. <i>Molecular Aspects of Medicine</i> , 2005, 26, 181-201.	2.7	96
178	Mechanisms of sex steroid effects on bone. <i>Biochemical and Biophysical Research Communications</i> , 2005, 328, 688-696.	1.0	329
179	Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. <i>Clinica Chimica Acta</i> , 2005, 360, 81-86.	0.5	269
180	Effect of oral contraceptive treatment on bone mass acquisition in skeletally immature young female rats. <i>Contraception</i> , 2005, 71, 362-371.	0.8	9
181	Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. <i>Steroids</i> , 2005, 70, 847-855.	0.8	37

#	ARTICLE	IF	CITATIONS
182	Skeletal morbidity in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 59-64.	0.6	64
183	Bone Remodeling in Post-menopausal Osteoporosis. <i>Journal of Dental Research</i> , 2006, 85, 584-595.	2.5	259
184	Effects of menopause and postmenopausal tibolone treatment on plasma TNF α , IL-4, IL-10, IL-12 cytokine pattern and some bone turnover markers. <i>Pharmacological Research</i> , 2006, 53, 367-371.	3.1	36
185	Calcium in Human Health. , 2006, , .		46
186	The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: Potential steroid-sparing role for DHEA. <i>Cytokine</i> , 2006, 36, 57-68.	1.4	21
187	Sex Steroid Effects on Bone Metabolism. , 2006, , 327-343.		0
188	The Role of RANK, RANK Ligand and Osteoprotegerin in the Lytic Effects and Growth of Bone Metastases. , 2006, , 51-62.		0
189	Low bone-mineral density in patients with HIV: pathogenesis and clinical significance. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2006, 13, 497-502.	0.6	13
190	Synovial fluid macrophages are capable of osteoclast formation and resorption. <i>Journal of Pathology</i> , 2006, 208, 35-43.	2.1	84
191	Cancer treatment-induced bone loss: A review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 156-166.	0.7	0
192	Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. <i>Clinical Endocrinology</i> , 2006, 64, 652-658.	1.2	73
193	Development of renal bone disease. <i>European Journal of Clinical Investigation</i> , 2006, 36, 2-12.	1.7	22
194	Prevention and treatment of osteoporosis in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 797-813.	0.9	75
195	Direct and Indirect Estrogen Actions on Osteoblasts and Osteoclasts. <i>Annals of the New York Academy of Sciences</i> , 2006, 1068, 173-179.	1.8	116
196	Effects of Anticatabolic and Anabolic Therapies at the Tissue Level. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2006, 4, 177-196.	1.3	1
197	Serum markers of bone turnover in dialyzed patients separated according to age. <i>International Urology and Nephrology</i> , 2006, 38, 311-316.	0.6	6
198	Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies. <i>Current Osteoporosis Reports</i> , 2006, 4, 28-33.	1.5	57
199	Osteoprotegerin as a potential therapy for osteoporosis. <i>Current Rheumatology Reports</i> , 2006, 8, 50-54.	2.1	12

#	ARTICLE	IF	CITATIONS
200	In vitro evaluation of the direct effect of estradiol on human osteoblasts (HOB) and human mesenchymal stem cells (h-MSCs). <i>Injury</i> , 2006, 37, S33-S42.	0.7	39
201	SERUM OSTEOPROTEGERIN AND RANKL LEVELS IN CHRONIC ALCOHOLIC LIVER DISEASE. <i>Alcohol and Alcoholism</i> , 2006, 41, 261-266.	0.9	64
202	Effects of Selective Testosterone and Estradiol Withdrawal on Skeletal Sensitivity to Parathyroid Hormone in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1069-1075.	1.8	31
203	Aromatase Inhibitors and Bone Health in Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5305-5312.	0.8	111
204	Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis. <i>Women's Health</i> , 2006, 2, 517-525.	0.7	9
205	Low Bone Mineral Density, HIV Infection, and Women: Fracture or Fiction?. <i>Clinical Infectious Diseases</i> , 2006, 42, 1021-1023.	2.9	20
206	Hormone Replacement Therapy in Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , 2006, 2, 251-260.	0.4	2
207	Skeletal Complications of Breast Cancer Therapies. <i>Clinical Cancer Research</i> , 2006, 12, 6309s-6314s.	3.2	87
208	RANK ligand inhibition with denosumab for the management of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1041-1050.	1.4	47
209	Polymorphisms at the Osteoprotegerin and Interleukin-6 Genes in Relation to First-Ever Stroke. <i>Cerebrovascular Diseases</i> , 2007, 24, 418-425.	0.8	21
210	Signaling Axis in Osteoclast Biology and Therapeutic Targeting in the RANKL/RANK/OPG System. <i>American Journal of Nephrology</i> , 2007, 27, 466-478.	1.4	69
211	The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor κ B ligand with bone mineral density in older adults: the Rancho Bernardo Study. <i>European Journal of Endocrinology</i> , 2007, 156, 555-562.	1.9	69
212	HRT and the Young at Heart. <i>New England Journal of Medicine</i> , 2007, 356, 2639-2641.	13.9	112
213	The Role of Receptor Activator of Nuclear Factor- κ B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4514-4521.	1.8	226
214	Osteoimmunology. <i>International Archives of Allergy and Immunology</i> , 2007, 143, 31-48.	0.9	123
215	Gene therapy methods in bone and joint disorders. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2007, 78, 2-64.	1.2	47
216	The Biology of Aseptic Osteolysis. <i>Clinical Orthopaedics and Related Research</i> , 2007, 460, 240-252.	0.7	284
217	The Relationship between Serum Levels of Estradiol and Osteoprotegerin in Patients with Anorexia Nervosa. <i>Endocrine Journal</i> , 2007, 54, 953-959.	0.7	27

#	ARTICLE	IF	CITATIONS
218	B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. <i>Blood</i> , 2007, 109, 3839-3848.	0.6	399
219	Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. <i>Menopause</i> , 2007, 14, 38-44.	0.8	26
220	The Effect of Estrogen Deficiency on Receptor Activator of Nuclear Factor Kappa B Ligand and Osteoprotegerin Synthesis in Periapical Lesions Induced in Rats. <i>Journal of Endodontics</i> , 2007, 33, 1053-1056.	1.4	15
221	Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. <i>Maturitas</i> , 2007, 56, 38-44.	1.0	34
222	Role of RANKL inhibition in osteoporosis. <i>Arthritis Research and Therapy</i> , 2007, 9, S3.	1.6	66
223	MARKERS OF BONE METABOLISM IN EUGONADAL FEMALE PATIENTS WITH \hat{I}^2 -THALASSEMIA MAJOR. <i>Pediatric Hematology and Oncology</i> , 2007, 24, 481-491.	0.3	10
224	Influence of hormones on osteogenic differentiation processes of mesenchymal stem cells. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 59-78.	1.2	2
225	Effects of Adrenal Steroids on the Bone Metabolism of Children with Congenital Adrenal Hyperplasia. <i>Annals of the New York Academy of Sciences</i> , 2007, 1117, 345-351.	1.8	17
226	Regulation of Bone Turnover by Sex Steroids in Men. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 705-714.	3.1	33
227	Bone loss in patients with breast or prostate cancer. <i>Current Osteoporosis Reports</i> , 2007, 5, 170-178.	1.5	13
228	Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E2 and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. <i>Journal of Nutritional Biochemistry</i> , 2007, 18, 54-63.	1.9	50
230	Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. <i>Osteoporosis International</i> , 2008, 19, 193-199.	1.3	49
231	Inhibition of osteoblastic metalloproteinases in mice prevents bone loss induced by oestrogen deficiency. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 1803-1817.	1.2	24
232	RANK/RANKL: Regulators of Immune Responses and Bone Physiology. <i>Annals of the New York Academy of Sciences</i> , 2008, 1143, 123-150.	1.8	355
233	RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 672-682.	3.1	119
234	OPG and sRANKL Serum Concentrations in Osteopenic, Postmenopausal Women After 2-Year Genistein Administration. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 715-720.	3.1	67
235	The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL. <i>Hemodialysis International</i> , 2008, 12, 100-107.	0.4	34
236	Dimorphic effects of Notch signaling in bone homeostasis. <i>Nature Medicine</i> , 2008, 14, 299-305.	15.2	361

#	ARTICLE	IF	CITATIONS
237	An acute injection of Porphyromonas gingivalis lipopolysaccharide modulates the OPG/RANKL system and interleukin-6 in an ovariectomized mouse model. Oral Microbiology and Immunology, 2008, 23, 220-225.	2.8	6
238	Influence of RANKL inhibition on immune system in the treatment of bone diseases. Joint Bone Spine, 2008, 75, 5-10.	0.8	43
239	Effects of alkylphenols on bone metabolism in vivo and in vitro. Toxicology Letters, 2008, 181, 13-18.	0.4	26
240	Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Research and Therapy, 2008, 10, R2.	1.6	27
241	Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Molecular and Cellular Endocrinology, 2008, 289, 38-48.	1.6	39
242	Inhibition of RANK/RANKL signal transduction pathway: A promising approach for osteoporosis treatment. Medical Hypotheses, 2008, 71, 256-258.	0.8	24
243	Pathogenesis of calciphylaxis: Hans Selye to nuclear factor κ -B. Journal of the American Academy of Dermatology, 2008, 58, 458-471.	0.6	169
244	Bone remodeling: A review of the bone microenvironment perspective for fragility fracture (osteoporosis) of the hip. Seminars in Cell and Developmental Biology, 2008, 19, 467-472.	2.3	37
245	Ethanol extract of Actaea racemosa (black cohosh) potentiates bone nodule formation in MC3T3-E1 preosteoblast cells. Bone, 2008, 43, 567-573.	1.4	21
246	Estrogen and bone: Insights from estrogen-resistant, aromatase-deficient, and normal men. Bone, 2008, 43, 414-417.	1.4	40
247	17 β -Estradiol inhibits osteoprotegerin production by the estrogen receptor- α -positive human breast cancer cell line MCF-7. Biochemical and Biophysical Research Communications, 2008, 368, 736-741.	1.0	24
248	Osteoclasts – the innate immune cells of the bone. Autoimmunity, 2008, 41, 183-194.	1.2	56
249	Pathophysiology of Osteoporosis. , 2008, , 1635-1647.		1
250	Receptor Activator of Nuclear Factor κ B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease. Endocrine Reviews, 2008, 29, 155-192.	8.9	705
251	Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. Journal of Endocrinological Investigation, 2008, 31, 416-421.	1.8	20
252	Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. European Journal of Endocrinology, 2008, 159, 225-232.	1.9	18
253	Regulation of Bone Cell Function by Estrogens. , 2008, , 383-423.		1
254	Root resorption and the OPG/RANKL/RANK system: a mini review. Journal of Oral Science, 2008, 50, 367-376.	0.7	98

#	ARTICLE	IF	CITATIONS
255	Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor κ B ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. <i>Menopause</i> , 2008, 15, 357-362.	0.8	14
256	Denosumab: an investigational drug for the management of postmenopausal osteoporosis. <i>Biologics: Targets and Therapy</i> , 2008, 2, 645.	3.0	24
257	Estrogens and Progestins. , 2008, , 855-885.		9
258	Development of the Skeleton. , 2008, , 241-269.		4
260	Apoptosis of Bone Cells. , 2008, , 237-261.		10
261	Pharmacotherapy Options in Cancer Treatment-induced Bone Loss: Focus on Bisphosphonates. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2064.	0.1	0
262	Implications of Measuring Soluble Receptor Activators of Nuclear Factor- κ B Ligand and Osteoprotegerin in Bone Metabolism of Elderly Women. <i>Gerontology</i> , 2009, 55, 275-280.	1.4	16
263	Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors, Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after Viral Hepatitis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4844-4850.	1.8	41
264	Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases. <i>Current Cancer Drug Targets</i> , 2009, 9, 834-842.	0.8	14
265	Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis. <i>Hormone and Metabolic Research</i> , 2009, 41, 721-729.	0.7	91
266	Prevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies. <i>Postgraduate Medicine</i> , 2009, 121, 5-17.	0.9	45
267	Novel Functions of RANK(L) Signaling in the Immune System. <i>Advances in Experimental Medicine and Biology</i> , 2009, 658, 77-94.	0.8	42
268	New hypotheses on the function of the avian shell gland derived from microarray analysis comparing tissue from juvenile and sexually mature hens. <i>General and Comparative Endocrinology</i> , 2009, 163, 225-232.	0.8	45
269	Coumestrol promotes proliferation and osteoblastic differentiation in rat bone marrow stromal cells. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2009, 90B, 621-628.	1.6	20
270	Therapeutic implications of osteoprotegerin. <i>Cancer Cell International</i> , 2009, 9, 26.	1.8	38
271	Involvement of molecular mimicry between human T-cell leukemia virus type 1 gp46 and osteoprotegerin in induction of hypercalcemia. <i>Cancer Science</i> , 2009, 100, 490-496.	1.7	10
272	ESCI award lecture: from a little mouse to rationale medicine for bone loss. <i>European Journal of Clinical Investigation</i> , 2009, 39, 842-850.	1.7	2
273	EFFECT OF BLACK COHOSH ON BIOCHEMICAL MARKERS OF BONE REMODELING IN POSTMENOPAUSAL WOMEN. <i>Journal of Midwifery and Women's Health</i> , 2009, 54, 424-424.	0.7	2

#	ARTICLE	IF	CITATIONS
274	The effect of exercise and estrogen on osteoprotegerin in premenopausal women. <i>Bone</i> , 2009, 44, 137-144.	1.4	16
275	RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 113, 46-51.	1.2	38
276	The effect of sex hormones on bone metabolism of the otic capsule – an overview. <i>Hearing Research</i> , 2009, 252, 56-60.	0.9	52
277	RANKL inhibition for the management of patients with benign metabolic bone disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1085-1102.	1.9	30
278	The Impact of Sex Hormone Changes on Bone Mineral Deficit in Chronic Renal Failure. <i>Endocrine Research</i> , 2009, 34, 90-99.	0.6	8
279	Dietary $\hat{3}$ -Aminobutyric Acid Affects the Brain Protein Synthesis Rate in Ovariectomized Female Rats. <i>Journal of Nutritional Science and Vitaminology</i> , 2009, 55, 75-80.	0.2	34
280	Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone). <i>Current Rheumatology Reviews</i> , 2009, 5, 98-110.	0.4	8
281	Receptor activator of nuclear factor- $\&$ kappa;B ligand and osteoprotegerin: maintaining the balance to prevent bone loss. <i>Clinical Interventions in Aging</i> , 2010, 5, 345.	1.3	141
282	Translational Endocrinology & Metabolism: Osteoporosis Update. <i>Translational Endocrinology & Metabolism</i> , 2010, , .	0.2	0
283	Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. <i>Osteoporosis International</i> , 2010, 21, 1657-1680.	1.3	89
284	Gene expression profiles of disc tissues and peripheral blood mononuclear cells from patients with degenerative discs. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 209-219.	1.3	21
285	Glycitein decreases the generation of murine osteoclasts and increases apoptosis. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 446-451.	0.5	11
286	Cancer Therapies and Bone Health. <i>Current Rheumatology Reports</i> , 2010, 12, 177-185.	2.1	16
287	No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year. <i>Nutrition Journal</i> , 2010, 9, 1.	1.5	223
288	Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene. <i>Archives of Oral Biology</i> , 2010, 55, 52-59.	0.8	44
289	New treatment targets in osteoporosis. <i>Joint Bone Spine</i> , 2010, 77, 222-228.	0.8	45
290	Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2438-2446.	3.1	44
291	Nouvelles cibles thÃ©rapeutiques dans lâ€™ostÃ©oporose. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010, 77, 257-263.	0.0	1

#	ARTICLE	IF	CITATIONS
292	Osteoprotective effects of Fructus Ligustri Lucidi aqueous extract in aged ovariectomized rats. Chinese Medicine, 2010, 5, 39.	1.6	32
293	Bone Changes and Fracture Related to Menstrual Cycles and Ovulation. Critical Reviews in Eukaryotic Gene Expression, 2010, 20, 213-233.	0.4	18
294	Influencing the Effect of Treatment of Diseases Related to Bone Remodelling by Dynamic Loading. , 2010, , .		1
295	Structure and Function of Tumor Necrosis Factor (TNF) at the Cell Surface. , 2010, , 265-275.		4
296	Denosumab for the Management of Postmenopausal Osteoporosis. Postgraduate Medicine, 2010, 122, 176-187.	0.9	10
297	Pathogenesis of Osteoporosis. Translational Endocrinology & Metabolism, 2010, 1, 55-86.	0.2	16
298	The Endogenous Selective Estrogen Receptor Modulator 27-Hydroxycholesterol Is a Negative Regulator of Bone Homeostasis. Endocrinology, 2010, 151, 3675-3685.	1.4	96
299	Physiology of Bone Loss. Radiologic Clinics of North America, 2010, 48, 483-495.	0.9	208
300	Osteoporosis and Osteomalacia. Rheumatic Disease Clinics of North America, 2010, 36, 665-680.	0.8	15
301	Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 294-299.	1.2	26
302	Vitamin D supplementation suppresses age-induced bone turnover in older women who are vitamin D deficient. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 293-296.	1.2	29
303	Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat. Trends in Endocrinology and Metabolism, 2010, 21, 411-418.	3.1	37
304	Female reproductive system and bone. Archives of Biochemistry and Biophysics, 2010, 503, 118-128.	1.4	138
305	Estrogen Inhibits Vascular Calcification via Vascular RANKL System. Circulation Research, 2010, 107, 466-475.	2.0	173
307	Genetics of osteoporosis: perspectives for personalized medicine. Personalized Medicine, 2010, 7, 655-668.	0.8	13
308	Molecular mechanisms for regulation of intestinal calcium absorption by vitamin D and other factors. Critical Reviews in Clinical Laboratory Sciences, 2010, 47, 181-195.	2.7	177
310	The Role of the Immune System in the Development of Osteoporosis. , 2011, , 269-299.		2
311	Osteoimmunology: The Bone-Immune Crosstalk. , 2011, , 1-37.		2

#	ARTICLE	IF	CITATIONS
312	Estrogens in rheumatoid arthritis; the immune system and bone. <i>Molecular and Cellular Endocrinology</i> , 2011, 335, 14-29.	1.6	100
313	LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF- κ B ligand (RANKL) and interleukin-6 production by human osteoblastic cells. <i>Molecular and Cellular Endocrinology</i> , 2011, 337, 43-51.	1.6	13
314	RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. <i>Trends in Endocrinology and Metabolism</i> , 2011, 22, 188-194.	3.1	49
315	The many roles of RANKL-RANK signaling in bone, breast and cancer. <i>IBMS BoneKEy</i> , 2011, 8, 237-256.	0.1	10
316	Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. <i>Breast Cancer Research</i> , 2011, 13, 205.	2.2	92
317	Osteoporosis: now and the future. <i>Lancet, The</i> , 2011, 377, 1276-1287.	6.3	1,973
318	Effects of <i>Sideritis euboea</i> (Lamiaceae) Aqueous Extract on IL-6, OPG and RANKL Secretion by Osteoblasts. <i>Natural Product Communications</i> , 2011, 6, 1934578X1100601.	0.2	8
319	Clinical utility of denosumab for treatment of bone loss in men and women. <i>Clinical Interventions in Aging</i> , 2011, 6, 119.	1.3	31
321	Osteoprotegerin in pregnant adolescents differs by race and is related to infant birth weight <i>z</i> -score. <i>Journal of Developmental Origins of Health and Disease</i> , 2011, 2, 272-279.	0.7	15
322	Direct effects of estrogen on differentiation and apoptosis of osteoclasts. <i>Orthodontic Waves</i> , 2011, 70, 8-14.	0.2	4
323	Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. <i>Archives of Oral Biology</i> , 2011, 56, 212-219.	0.8	14
324	Conditional expression of constitutively active estrogen receptor β in osteoblasts increases bone mineral density in mice. <i>FEBS Letters</i> , 2011, 585, 1303-1309.	1.3	22
325	Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology. <i>Acta Histochemica</i> , 2011, 113, 73-81.	0.9	19
326	Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 863-870.	1.1	15
327	Osteoblast physiology in normal and pathological conditions. <i>Cell and Tissue Research</i> , 2011, 343, 289-302.	1.5	268
328	Relationship between serum RANKL and RANKL in bone. <i>Osteoporosis International</i> , 2011, 22, 2597-2602.	1.3	62
329	The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: Is a revision needed?. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 441-451.	3.1	274
330	Sex-specific effects of estrogen and androgen on gene expression in human monocyte-derived osteoclasts. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 3714-3721.	1.2	25

#	ARTICLE	IF	CITATIONS
331	Effect of Endocrine Therapies on Bone in Breast Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 308-319.	1.8	51
332	Roles of transactivating functions 1 and 2 of estrogen receptor- β in bone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6288-6293.	3.3	88
333	The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease. <i>Current Medicinal Chemistry</i> , 2011, 18, 4813-4819.	1.2	14
334	The Genetics of Bone Loss: Challenges and Prospects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1258-1268.	1.8	32
335	Circulating osteoprotegerin and soluble receptor activator of nuclear factor κ B ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. <i>European Journal of Endocrinology</i> , 2011, 164, 61-68.	1.9	47
336	Integrated Imaging Approach to Osteoporosis: State-of-the-Art Review and Update. <i>Radiographics</i> , 2011, 31, 1343-1364.	1.4	145
337	Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. <i>Indian Journal of Endocrinology and Metabolism</i> , 2011, 15, 175.	0.2	121
338	The Effects of Tualang Honey on Bone Metabolism of Postmenopausal Women. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-7.	0.5	16
339	Mechanisms of bone anabolism regulated by statins. <i>Bioscience Reports</i> , 2012, 32, 511-519.	1.1	81
340	Interleukin 6, RANKL, and Osteoprotegerin Expression by Chikungunya Virus-Infected Human Osteoblasts. <i>Journal of Infectious Diseases</i> , 2012, 206, 455-457.	1.9	71
341	The Anti-Inflammatory, Phytoestrogenic, and Antioxidative Role of <i>Labisia pumila</i> in Prevention of Postmenopausal Osteoporosis. <i>Advances in Pharmacological Sciences</i> , 2012, 2012, 1-7.	3.7	22
342	Aging and bone loss: new insights for the clinician. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 61-76.	1.2	371
343	The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. <i>Annals of Oncology</i> , 2012, 23, 2782-2790.	0.6	35
344	TGF- β 2 Mediates Suppression of Adipogenesis by Estradiol through Connective Tissue Growth Factor Induction. <i>Endocrinology</i> , 2012, 153, 254-263.	1.4	36
345	Osteoporosis en enfermedades reumáticas. <i>Revista Médica Clínica Las Condes</i> , 2012, 23, 425-431.	0.2	0
346	Selective Regulation of Osteoblastic OPG and RANKL by Dehydroepiandrosterone Through Activation of the Estrogen Receptor β -mediated MAPK Signaling Pathway. <i>Hormone and Metabolic Research</i> , 2012, 44, 494-500.	0.7	14
347	A standardized phytopreparation from an Indian medicinal plant (<i>Dalbergia sissoo</i>) has antiresorptive and bone-forming effects on a postmenopausal osteoporosis model of rat. <i>Menopause</i> , 2012, 19, 1336-1346.	0.8	40
348	Hormonal contraception and bone metabolism: a systematic review. <i>Contraception</i> , 2012, 86, 606-621.	0.8	80

#	ARTICLE	IF	CITATIONS
349	Corticosteroid-Induced Osteoporosis. American Journal of Clinical Dermatology, 2012, 13, 167-190.	3.3	13
350	Gingival crevicular fluid levels of osteoprotegerin (OPG) in premenopausal and postmenopausal women with or without chronic periodontitis. Journal of Dentistry, 2012, 40, 364-371.	1.7	14
351	Osteoporosisâ€™a risk factor for cardiovascular disease?. Nature Reviews Rheumatology, 2012, 8, 587-598.	3.5	152
352	Estrogen and the skeleton. Trends in Endocrinology and Metabolism, 2012, 23, 576-581.	3.1	604
354	Bone cells and the mechanisms of bone remodelling. Frontiers in Bioscience - Elite, 2012, E4, 2302.	0.9	49
355	A Systems Approach to Understanding Bone Cell Interactions in Health and Disease. , 2012, , .		11
356	Targeted Breast Cancer Nanotherapeutics: Options and Opportunities with Estrogen Receptors. Critical Reviews in Therapeutic Drug Carrier Systems, 2012, 29, 421-446.	1.2	17
357	HIV: Inflammation and Bone. Current HIV/AIDS Reports, 2012, 9, 16-25.	1.1	73
358	Bisphosphonates: effects on osteoblast. European Journal of Clinical Pharmacology, 2012, 68, 1013-1018.	0.8	76
359	Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data. Clinical Therapeutics, 2012, 34, 521-536.	1.1	110
361	The role of estrogen receptor β in the regulation of bone and growth plate cartilage. Cellular and Molecular Life Sciences, 2013, 70, 4023-4037.	2.4	85
362	Cytokines and the Pathogenesis of Osteoporosis. , 2013, , 915-937.		1
363	Development of the Skeleton. , 2013, , 97-126.		8
364	Regulation of Bone Cell Function by Estrogens. , 2013, , 329-344.		0
365	Effects of Estrogen Deficiency and/or Caffeine Intake on Alveolar Bone Loss, Density, and Healing: A Study in Rats. Journal of Periodontology, 2013, 84, 839-849.	1.7	36
366	Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats. Rheumatology International, 2013, 33, 1135-1141.	1.5	44
367	Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Critical Reviews in Oncology/Hematology, 2013, 87, 101-111.	2.0	46
368	Age and gender predict OPG level and OPG/sRANKL ratio in maintenance hemodialysis patients. Advances in Medical Sciences, 2013, 58, 382-387.	0.9	8

#	ARTICLE	IF	CITATIONS
369	Does estrogen play a role in response to adjuvant bone-targeted therapies?. <i>Journal of Bone Oncology</i> , 2013, 2, 167-173.	1.0	6
370	<i>Labisia pumila</i> regulates bone-related genes expressions in postmenopausal osteoporosis model. <i>BMC Complementary and Alternative Medicine</i> , 2013, 13, 217.	3.7	16
372	Inactivation of estrogen receptor β in bone-forming cells induces bone loss in female mice. <i>FASEB Journal</i> , 2013, 27, 478-488.	0.2	74
373	The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oysterols: Implications for the treatment and prevention of osteoporosis. <i>Bone</i> , 2013, 53, 42-50.	1.4	96
374	Neuropeptide Y and Bone Formation. , 2013, , 39-49.		0
375	Disruption of claudin-18 diminishes ovariectomy-induced bone loss in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E531-E537.	1.8	8
376	Endogenous Glucocorticoids and Bone. <i>Bone Research</i> , 2013, 1, 107-119.	5.4	37
377	Bone mineral density in adult coeliac disease: An updated review. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 154-162.	0.1	55
378	Upregulation of genes related to bone formation by γ -amino butyric acid and γ -oryzanol in germinated brown rice is via the activation of GABAB-receptors and reduction of serum IL-6 in rats. <i>Clinical Interventions in Aging</i> , 2013, 8, 1259.	1.3	26
379	HIV and Bone Disease: A Perspective of the Role of microRNAs in Bone Biology upon HIV Infection. <i>Journal of Osteoporosis</i> , 2013, 2013, 1-8.	0.1	7
380	Postmenopausal Osteoporosis: The Role of Immune System Cells. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-6.	3.3	115
381	A review of denosumab for the treatment of osteoporosis. <i>Patient Preference and Adherence</i> , 2014, 8, 463.	0.8	56
382	The RANK/ RANKL/ OPG interaction in the repair of autogenous bone grafts in female rats with estrogen deficiency. <i>Brazilian Oral Research</i> , 2014, 28, 1-9.	0.6	15
383	Fisiología del hueso y marcadores bioquímicos del recambio óseo. , 2014, , 19-42.		0
384	Unraveling the associations of osteoprotegerin gene with production traits in a paternal broiler line. <i>SpringerPlus</i> , 2014, 3, 682.	1.2	16
385	The effects of <i>Labisia pumila</i> on postmenopausal osteoporotic rat model: Dose and time-dependent micro-CT analysis. <i>Journal of X-Ray Science and Technology</i> , 2014, 22, 503-518.	0.7	15
386	Deregulation of Bone Forming Cells in Bone Diseases and Anabolic Effects of Strontium-Containing Agents and Biomaterials. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	39
387	Emerging Multifunctional Roles of Claudin Tight Junction Proteins in Bone. <i>Endocrinology</i> , 2014, 155, 2363-2376.	1.4	17

#	ARTICLE	IF	CITATIONS
388	RANKL/RANK “ From bone physiology to breast cancer. Cytokine and Growth Factor Reviews, 2014, 25, 205-214.	3.2	48
389	Conjugated Linoleic Acid Prevents Ovariectomy-Induced Bone Loss in Mice by Modulating Both Osteoclastogenesis and Osteoblastogenesis. Lipids, 2014, 49, 211-224.	0.7	17
390	Osteoprotective effect of soybean and sesame oils in ovariectomized rats via estrogen-like mechanism. Cytotechnology, 2014, 66, 335-343.	0.7	23
391	Bone-Implant Interface in Orthopedic Surgery. , 2014, , .		7
392	Differentially expressed genes and signalling pathways are involved in mouse osteoblast-like MC3T3-E1 cells exposed to 17- β estradiol. International Journal of Oral Science, 2014, 6, 142-149.	3.6	23
393	Endocrine aspects of bone metastases. Lancet Diabetes and Endocrinology,the, 2014, 2, 500-512.	5.5	95
394	Effect of Estrogen and Food Hardness on Metabolism and Turnover of Condylar Cartilage. Journal of Oral and Facial Pain and Headache, 2015, 29, 297-307.	0.7	5
395	24 Hours Urinary Hydroxyproline - A Noninvasive, Cost-Effective and Early Biochemical Marker Which May be Used to Screen the Osteoporotic Lesion in Postmenopausal Women. Asian Journal of Medical Sciences, 2015, 6, 21-24.	0.0	0
396	Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association. Bone, 2015, 75, 96-104.	1.4	39
397	The RANKL-RANK Story. Gerontology, 2015, 61, 534-542.	1.4	127
398	Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies. Molecular Cancer Research, 2015, 13, 819-827.	1.5	10
399	The Role of Estrogen Receptor in Bone Cells. Clinical Reviews in Bone and Mineral Metabolism, 2015, 13, 105-112.	1.3	5
400	The Pathophysiology and Treatment of Osteoporosis. Clinical Therapeutics, 2015, 37, 1837-1850.	1.1	196
401	17 β -Estradiol-Loaded PEGylated Upconversion Nanoparticles as a Bone-Targeted Drug Nanocarrier. ACS Applied Materials & Interfaces, 2015, 7, 15803-15811.	4.0	26
402	Minireview: Nuclear Receptor Regulation of Osteoclast and Bone Remodeling. Molecular Endocrinology, 2015, 29, 172-186.	3.7	31
403	Cellular and molecular mechanisms of chikungunya pathogenesis. Antiviral Research, 2015, 120, 165-174.	1.9	52
404	Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study. BMC Musculoskeletal Disorders, 2015, 16, 227.	0.8	7
405	Osteoprotegerin in <sc>T</sc>urner syndrome “ relationship to aortic diameter. Clinical Endocrinology, 2015, 82, 397-403.	1.2	2

#	ARTICLE	IF	CITATIONS
406	Prevalence and correlates of mitral annular calcification in adults with chronic kidney disease: Results from CRIC study. <i>Atherosclerosis</i> , 2015, 242, 117-122.	0.4	29
407	Effects of Roughly Focused Extracorporeal Shock Waves Therapy on the Expressions of Bone Morphogenetic Protein-2 and Osteoprotegerin in Osteoporotic Fracture in Rats. <i>Chinese Medical Journal</i> , 2016, 129, 2567-2575.	0.9	29
408	RANK and RANKL of Bones, T Cells, and the Mammary Glands. , 2016, , 121-142.		1
409	Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study. <i>PLoS ONE</i> , 2016, 11, e0166792.	1.1	18
410	Major osteoporotic fragility fractures: Risk factor updates and societal impact. <i>World Journal of Orthopedics</i> , 2016, 7, 171.	0.8	344
411	Deletion of Estrogen Receptor Beta in Osteoprogenitor Cells Increases Trabecular but Not Cortical Bone Mass in Female Mice. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 606-614.	3.1	35
412	Differentiation of skeletal osteogenic progenitor cells to osteoblasts with 3,4-diarylbenzopyran based amide derivatives: Novel osteogenic agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 82-99.	2.6	13
413	MODEL-BASED ANALYSIS OF IGF-1 EFFECT ON OSTEOBLAST AND OSTEOCLAST REGULATION IN BONE TURNOVER. <i>Journal of Biological Systems</i> , 2016, 24, 63-89.	0.5	5
414	Design and synthesis of 3-arylbenzopyran based non-steroidal vitamin-D ₃ mimics as osteogenic agents. <i>MedChemComm</i> , 2016, 7, 2381-2394.	3.5	7
415	IGF-1 Regulates Vertebral Bone Aging Through Sex-Specific and Time-Dependent Mechanisms. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 443-454.	3.1	41
416	p38 ^{Î±} MAPK Regulates Lineage Commitment and OPG Synthesis of Bone Marrow Stromal Cells to Prevent Bone Loss under Physiological and Pathological Conditions. <i>Stem Cell Reports</i> , 2016, 6, 566-578.	2.3	32
417	Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis. <i>Molecular and Cellular Endocrinology</i> , 2016, 422, 182-191.	1.6	20
418	Induction of targeted osteogenesis with 3-aryl- 2H -benzopyrans and 3-aryl- 3H -benzopyrans: Novel osteogenic agents. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 158, 63-75.	1.2	8
419	Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008â€“2010 Korea National Health and Nutrition Examination Surveys. <i>Hepatology International</i> , 2016, 10, 470-477.	1.9	16
421	Jumping exercise preserves bone mineral density and mechanical properties in osteopenic ovariectomized rats even following established osteopenia. <i>Osteoporosis International</i> , 2017, 28, 1461-1471.	1.3	13
422	Estrogens and androgens inhibit association of RANKL with the preâ€œosteoblast membrane through postâ€œtranslational mechanisms. <i>Journal of Cellular Physiology</i> , 2017, 232, 3798-3807.	2.0	15
423	Evaluation of anti-osteoporotic activity of butanolic fraction from <i>Passiflora foetida</i> in ovariectomy-induced bone loss in mice. <i>Biomedicine and Pharmacotherapy</i> , 2017, 88, 804-813.	2.5	15
424	Estrogen stimulates osteoprotegerin expression via the suppression of miR-145 expression in MC-63 cells. <i>Molecular Medicine Reports</i> , 2017, 15, 1539-1546.	1.1	40

#	ARTICLE	IF	CITATIONS
425	Synergistic attenuation of ovariectomy-induced bone loss by combined use of fish oil and 17 β -oestradiol. <i>British Journal of Nutrition</i> , 2017, 117, 479-489.	1.2	9
426	Efficacy of a Cellular Bone Allograft for Foot and Ankle Arthrodesis and Revision Nonunion Procedures. <i>Foot and Ankle International</i> , 2017, 38, 277-282.	1.1	20
427	Exercise and bone health across the lifespan. <i>Biogerontology</i> , 2017, 18, 931-946.	2.0	155
428	Leptospirosis: Molecular trial path and immunopathogenesis correlated with dengue, malaria and mimetic hemorrhagic infections. <i>Acta Tropica</i> , 2017, 176, 206-223.	0.9	18
429	Osteoclasts: Essentials and Methods. <i>Learning Materials in Biosciences</i> , 2017, , 33-53.	0.2	1
430	Heartwood extract from <i>Dalbergia sissoo</i> promotes fracture healing and its application in ovariectomy-induced osteoporotic rats. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1381-1397.	1.2	15
431	Bone responses in health and infectious diseases: A focus on osteoblasts. <i>Journal of Infection</i> , 2017, 75, 281-292.	1.7	40
432	Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. <i>Scientific Reports</i> , 2017, 7, 6460.	1.6	150
433	Molecular signaling mechanisms behind polyphenol-induced bone anabolism. <i>Phytochemistry Reviews</i> , 2017, 16, 1183-1226.	3.1	67
434	An impulsive mathematical model of bone formation and resorption: effects of parathyroid hormone, calcitonin and impulsive estrogen supplement. <i>Advances in Difference Equations</i> , 2017, 2017, .	3.5	5
435	Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults. <i>Osteoporosis International</i> , 2017, 28, 2683-2689.	1.3	27
436	In Vitro Findings of Titanium Functionalized with Estradiol via Polydopamine Adlayer. <i>Journal of Functional Biomaterials</i> , 2017, 8, 45.	1.8	4
437	Nuclear Receptors in Skeletal Homeostasis. <i>Current Topics in Developmental Biology</i> , 2017, 125, 71-107.	1.0	15
438	Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats. <i>PLoS ONE</i> , 2017, 12, e0171276.	1.1	14
439	Bone mineral density and body composition in children with congenital adrenal hyperplasia. <i>Clinical Endocrinology</i> , 2018, 88, 813-819.	1.2	16
440	Cancer Treatment and Bone Health. <i>Calcified Tissue International</i> , 2018, 102, 251-264.	1.5	60
441	Causes of low peak bone mass in women. <i>Maturitas</i> , 2018, 111, 61-68.	1.0	21
442	RANKL and RANK: From Mammalian Physiology to Cancer Treatment. <i>Trends in Cell Biology</i> , 2018, 28, 213-223.	3.6	72

#	ARTICLE	IF	CITATIONS
443	Effect of esculetin on bone metabolism in ovariectomized rats. <i>Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine</i> , 2018, 38, 896-903.	0.4	5
444	'Osteoimmunology' Offers New Perspectives for the Treatment of Pathological Bone Loss. <i>Current Pharmaceutical Design</i> , 2018, 23, 6272-6278.	0.9	23
445	Glucocorticoid-induced osteoporosis in systemic lupus erythematosus. <i>Rheumatology Practice and Research</i> , 2018, 3, 205990211880251.	0.0	0
448	Immunology of Osteoporosis. , 2018, , 1-21.		0
449	Dysregulation of the RANKL/RANK/OPG axis in thalassemia intermedia patients. <i>BMC Research Notes</i> , 2018, 11, 534.	0.6	9
450	Resolvin E1 Promotes Bone Preservation Under Inflammatory Conditions. <i>Frontiers in Immunology</i> , 2018, 9, 1300.	2.2	49
451	ST2 regulates bone loss in a site-dependent and estrogen-dependent manner. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 8511-8521.	1.2	18
452	Circulating Levels of Bone and Inflammatory Markers in Gestational Diabetes Mellitus. <i>BioResearch Open Access</i> , 2018, 7, 123-130.	2.6	13
453	Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1746-1754.	1.1	8
454	Ovariectomy increases RANKL protein expression in bone marrow adipocytes of C3H/HeJ mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E1050-E1054.	1.8	21
455	<p>Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD</p>. <i>Journal of Inflammation Research</i> , 2019, Volume 12, 99-108.	1.6	27
456	Osteoclastogenesis from bone marrow cells during estrogen-induced medullary bone formation in Japanese quails. <i>Journal of Molecular Histology</i> , 2019, 50, 389-404.	1.0	6
457	Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: Impact of anastrozole on bone mineral density and visceral adipose tissue. <i>Clinical Endocrinology</i> , 2019, 91, 124-130.	1.2	15
458	A polymorphism rs6815464 in the macrophage erythroblast attacher gene is associated with low bone mineral density in postmenopausal Japanese women. <i>Gene</i> , 2019, 700, 1-6.	1.0	6
459	Force-induced decline of TEA domain family member 1 contributes to osteoclastogenesis via regulation of Osteoprotegerin. <i>Archives of Oral Biology</i> , 2019, 100, 23-32.	0.8	9
460	Bone-Vascular Axis in Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 472-483.	0.6	53
461	Gonadal Hormones and Bone. <i>Handbook of Experimental Pharmacology</i> , 2019, 262, 65-91.	0.9	3
462	RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 12.	3.5	121

#	ARTICLE	IF	CITATIONS
463	Bone biomarkers in de novo renal transplant recipients. <i>Clinica Chimica Acta</i> , 2020, 501, 179-185.	0.5	9
464	Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1283.	1.3	42
465	Re-appraising the potential of naringin for natural, novel orthopedic biotherapies. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096613.	1.2	26
466	The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 583884.	1.7	14
467	Toward a Mathematical Modeling of Diseases's™ Impact on Bone Remodeling: Technical Review. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 584198.	2.0	18
468	Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127138.	1.0	2
469	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
470	Corylin, a flavonoid derived from <i>Psoralea Fructus</i> , induces osteoblastic differentiation via estrogen and Wnt/ β -catenin signaling pathways. <i>FASEB Journal</i> , 2020, 34, 4311-4328.	0.2	40
471	Cytokines and Bone: Osteoimmunology. <i>Handbook of Experimental Pharmacology</i> , 2020, 262, 177-230.	0.9	16
472	Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System. <i>Frontiers in Immunology</i> , 2020, 11, 58.	2.2	96
473	Interleukin 17A: a Janus-faced regulator of osteoporosis. <i>Scientific Reports</i> , 2020, 10, 5692.	1.6	14
474	Synthesis and biological activities of drugs for the treatment of osteoporosis. <i>European Journal of Medicinal Chemistry</i> , 2020, 197, 112313.	2.6	38
475	Extracellular Vesicle-Mediated Bone Remodeling and Bone Metastasis: Implications in Prostate Cancer. <i>Sub-Cellular Biochemistry</i> , 2021, 97, 297-361.	1.0	4
476	Role of the RANK/RANKL/OPG and Wnt/ β -Catenin Systems in CKD Bone and Cardiovascular Disorders. <i>Calcified Tissue International</i> , 2021, 108, 439-451.	1.5	41
477	Mechanobiological Behavior of a Pathological Bone. , 0, , .		4
478	The Effects of TGF- β 3, 17- β Estradiol and Bisphenol A on Osteoprotegerin Production in Osteoblasts. <i>Kocatepe Veteriner Dergisi</i> , 0, , .	0.2	0
479	Sex-related differences in bone metabolism in osteoporosis observational study. <i>Medicine (United Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	0.4	11
480	Roles of Nuclear Receptors in Vascular Calcification. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6491.	1.8	3

#	ARTICLE	IF	CITATIONS
481	Anti-Apoptotic and Antioxidant Activities of the Mitochondrial Estrogen Receptor Beta in N2A Neuroblastoma Cells. International Journal of Molecular Sciences, 2021, 22, 7620.	1.8	13
482	Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?. International Journal of Molecular Sciences, 2021, 22, 8932.	1.8	4
483	The hidden secrets of soluble RANKL in bone biology. Cytokine, 2021, 144, 155559.	1.4	16
484	Aromatic Bis[aminomethylidenebis(phosphonic)] Acids Prevent Ovariectomy-Induced Bone Loss and Suppress Osteoclastogenesis in Mice. International Journal of Molecular Sciences, 2021, 22, 9590.	1.8	1
485	Resveratrol Ameliorates Aortic Calcification in Ovariectomized Rats via SIRT1 Signaling. Current Issues in Molecular Biology, 2021, 43, 1057-1071.	1.0	12
486	Endocrinology of Bone and Growth Disorders. , 2021, , .		1
487	Cytokines and the pathogenesis of osteoporosis. , 2021, , 799-831.		1
488	Development of the skeleton. , 2021, , 39-73.		0
490	Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology, 2009, , .	0.8	6
491	OPG, RANKL, and RANK in Cancer Metastasis: Expression and Regulation. Cancer Treatment and Research, 2004, 118, 149-172.	0.2	28
492	Molecular Regulation of Calcium Metabolism. , 2006, , 163-189.		18
493	Bone and the Immune System. Molecular and Integrative Toxicology, 2017, , 363-398.	0.5	7
494	Introduction to Bone Development, Remodelling and Repair. Medical Radiology, 2008, , 1-23.	0.0	8
496	Sex Steroid Effects on Bone Metabolism. , 2006, , 327-343.		2
497	Vitamin D and Osteoclastogenesis. , 2005, , 665-685.		12
498	Regulation of Bone Cell Function by Estrogens. , 2001, , 305-337.		6
499	Bone Health and Osteoporosis Prevention and Treatment. Clinical Obstetrics and Gynecology, 2020, 63, 770-787.	0.6	23
500	Estrogen deficiency induces bone loss by enhancing T-cell production of TNF- α . Journal of Clinical Investigation, 2000, 106, 1229-1237.	3.9	597

#	ARTICLE	IF	CITATIONS
501	Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. Journal of Clinical Investigation, 2001, 108, 971-979.	3.9	155
502	Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. Journal of Clinical Investigation, 2002, 110, 1643-1650.	3.9	116
503	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. Journal of Clinical Investigation, 2003, 111, 1221-1230.	3.9	361
504	A crucial role for thiol antioxidants in estrogen-deficiency bone loss. Journal of Clinical Investigation, 2003, 112, 915-923.	3.9	218
505	M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone loss. Journal of Clinical Investigation, 2000, 105, 1279-1287.	3.9	90
506	Estrogen/Estrogen Receptor Alpha Signaling in Mouse Posterofrontal Cranial Suture Fusion. PLoS ONE, 2009, 4, e7120.	1.1	54
507	Interaction between osteoblast and osteoclast: impact in bone disease. Histology and Histopathology, 2004, 19, 1325-44.	0.5	149
508	Longitudinal evaluation of hepatic osteodystrophy in children and adolescents with chronic cholestatic liver disease. Brazilian Journal of Medical and Biological Research, 2010, 43, 1127-1134.	0.7	7
509	Association between estrogen receptor alpha gene polymorphisms and bone mineral density in Polish female patients with Graves' disease.. Acta Biochimica Polonica, 2011, 58, .	0.3	4
510	Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP/PKA/CREB pathway. Aging, 2020, 12, 8120-8136.	1.4	16
511	The expression of cystathionine gamma-lyase is regulated by estrogen receptor alpha in human osteoblasts. Oncotarget, 2017, 8, 101686-101696.	0.8	18
512	Interaction Between Bone and Muscle in Older Persons with Mobility Limitations. Current Pharmaceutical Design, 2014, 20, 3178-3197.	0.9	88
513	Autophagy: A Promising Target for Age-related Osteoporosis. Current Drug Targets, 2019, 20, 354-365.	1.0	18
514	The Impact of Menopause on Bone Fusion after the Single-Level Anterior Cervical Discectomy and Fusion. Journal of Korean Neurosurgical Society, 2013, 54, 496.	0.5	6
515	Bone and Joint Protection Ability of Ceramic Material with Biological Effects. Chinese Journal of Physiology, 2012, 55, 47-54.	0.4	35
516	The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox. Balkan Medical Journal, 2018, 35, 225-232.	0.3	9
517	Cell Interaction. , 2012, , .		5
518	<i>In vitro</i> evaluation of osteoprotegerin in chitosan for potential bone defect applications. PeerJ, 2016, 4, e2229.	0.9	11

#	ARTICLE	IF	CITATIONS
519	New Approaches to Osteoporosis Therapeutics. , 2001, , 769-818.		0
520	Colony-Stimulating Factors. , 2002, , 943-XXXVI.		1
521	Estrogens and Progestins. , 2002, , 655-675.		2
522	Mechanisms of Estrogen Action in Bone. , 2002, , 693-705.		0
523	Targeting the Osteoblast for Prevention and Treatment of Bone Diseases. , 2004, , 138-153.		0
524	The Role of Androgens and Estrogens in the Male Skeleton. , 2004, , 1021-1032.		0
525	Receptor activator of nuclear factor κ B ligand (RANKL) versus osteoprotegerin (OPG): the yin and yang of joint integrity. , 2004, , 221-267.		0
526	Osteoporosis and Vascular Calcification: Lesson from OPG KO Mice. Journal of Korean Endocrine Society, 2005, 20, 571.	0.1	0
527	Pathogenesis of Inflammation-Induced Bone Loss. , 2006, , 249-263.		0
530	Bone Density and Imaging of Osteoporosis. , 2010, , 1261-1291.		2
532	Osteoporozda Yeni Tedavi AjanlarÄ±. FTR - Turkiye Fiziksel Tip Ve Rehabilitasyon Dergisi, 2011, 57, 165-171.	0.1	0
533	Osteogenic Response of Human Osteoblasts Derived from Mandible and Maxilla: A Preliminary Study. The Journal of Korean Association of Maxillofacial Plastic and Reconstructive Surgeons, 2013, 35, 31-37.	0.1	0
534	The Biology of Aseptic Loosening. , 2014, , 139-157.		0
535	El hueso en la obesidad. CirugÃa bariÃtrica y metabolismo mineral Åseo. , 2014, , 237-250.		0
536	Patogenia de la osteoporosis. , 2014, , 53-62.		0
537	Regulatory Mechanisms of Bone Development and Function. Annals of Cytology and Pathology, 2016, 1, 005-017.	0.3	1
538	Immunopathology of the Musculoskeletal System. Molecular and Integrative Toxicology, 2017, , 615-648.	0.5	0
540	Immunology of Osteoporosis. , 2019, , 2469-2488.		0

#	ARTICLE	IF	CITATIONS
541	Biological characteristics of osteoporosis drugs: the effect of osteoblast-osteoclast coupling. <i>International Journal of Oral Biology: Official Journal of the Korean Academy of Oral Biology and the UCLA Dental Research Institute</i> , 2019, 44, 1-7.	0.1	2
543	New Generation of Meso and Antiproggestins (SPRMs) into the Osteoporosis Approach. <i>Molecules</i> , 2021, 26, 6491.	1.7	2
545	Physiology of Bone Mass Acquisition and Pathophysiology of Bone Mass Loss: Gender Differences. <i>Trends in Andrology and Sexual Medicine</i> , 2020, , 25-33.	0.1	0
546	Osteoprotegerin as a potential therapy for osteoporosis. <i>Current Osteoporosis Reports</i> , 2005, 3, 121-125.	1.5	2
547	Protective and curative role of vitamin D and hormones on the cadmium-induced inhibition of proliferation of human osteoblast cells. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2021, 32, 995-1000.	0.7	1
549	Indicators of Renal Glomerular and Tubular Functions in Patients with Beta-Thalassaemia Major: A cross sectional study at the Royal Hospital, Oman. <i>Sultan Qaboos University Medical Journal</i> , 2011, 11, 69-76.	0.3	3
550	HIV and bone metabolism. <i>Discovery Medicine</i> , 2011, 11, 385-93.	0.5	37
551	The influence of pregnancy and lactation on maternal bone health: a systematic review. <i>Journal of Family & Reproductive Health</i> , 2014, 8, 135-48.	0.4	37
553	The regulatory roles of long noncoding RNAs in osteoporosis. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5882-5907.	0.0	2
554	Osteoblast-activating peptide exhibits a specific distribution pattern in mouse ovary and may regulate ovarian steroids and local calcium levels. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 5796-5814.	0.0	1
555	Estrogens and phytoestrogens in body functions. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 648-663.	2.9	33
558	Applications of Calcium-Based Nanomaterials in Osteoporosis Treatment. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 424-443.	2.6	4
559	Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1393.	1.8	16
561	Ovariectomized rat model and shape variation in the bony labyrinth. <i>Anatomical Record</i> , 2022, 305, 3283-3296.	0.8	1
562	The Microbiota-Bone-Allergy Interplay. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 282.	1.2	5
563	Assessment of bone metabolism and fracture risk in obese men. <i>Annales Academiae Medicae Silesiensis</i> , 2022, 76, 5-13.	0.1	0
564	Postmenopausal osteoporosis: current status of bone densitometry. <i>Minerva Obstetrics and Gynecology</i> , 2021, 73, 730-743.	0.5	5
565	Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta. <i>Cells</i> , 2022, 11, 1357.	1.8	3

#	ARTICLE	IF	CITATIONS
566	Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, 14.	0.6	4
567	Hormone and receptor activator of NF- κ B (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women. <i>Breast Cancer Research</i> , 2022, 24, 28.	2.2	6
568	Bone Metastases: From Mechanisms to Treatment. <i>Seminars in Oncology Nursing</i> , 2022, , 151277.	0.7	5
569	RANKL elevation activates the NIK/NF- κ B pathway, inducing obesity in ovariectomized mice. <i>Journal of Endocrinology</i> , 2022, 254, 27-36.	1.2	3
571	The impact of sex steroids on osteonecrosis of the jaw. <i>Osteoporosis and Sarcopenia</i> , 2022, 8, 58-67.	0.7	4
573	Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial. <i>Phytomedicine</i> , 2022, 105, 154334.	2.3	6
574	Skeletal Effects of Inducible ER α Deletion in Osteocytes in Adult Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1750-1760.	3.1	7
575	A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8468.	1.8	9
576	Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study. <i>Medicina (Lithuania)</i> , 2022, 58, 976.	0.8	1
577	Employment of selective pharmacologically active natural compounds in treatment and management of osteoporosis. <i>Studies in Natural Products Chemistry</i> , 2022, , 161-241.	0.8	0
578	Estrogen enforces the integrity of blood vessels in the bone during pregnancy and menopause. , 2022, 1, 918-932.		7
579	Etiological factors of facial nerve stimulation in cochlear implant users. <i>Meditinskiy Sovet</i> , 2022, , 170-176.	0.1	0
580	RANKL and RANK in Cancer Therapy. <i>Physiology</i> , 2023, 38, 110-124.	1.6	1
582	Hypoxia-Inducible Factor α Signaling in the Skeletal System. <i>JBMR Plus</i> , 2023, 7, .	1.3	4